Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone

다국어 초록 (Multilingual Abstract)

Purpose: There is controversy surrounding the growth outcomes of treatment with gonadotropin-releasing hormone agonist (GnRHa) in central precocious puberty (CPP). We analyzed height preservation after treatment with GnRHa with and without growth hormone (GH) in girls with CPP.
Methods: We reviewed the medical records of 82 girls with idiopathic CPP who had been treated with GnRHa at Severance Children’s Hospital from 2004 to 2014. We assessed the changes in height standard deviation score (SDS) for bone age (BA), and compared adult height (AH) with midparental height (MPH) and predicted adult height (PAH) during treatment in groups received GnRHa alone (n=59) or GnRHa plus GH (n=23).
Results: In the GnRHa alone group, the height SDS for BA was increased during treatment. AH (160.4±4.23 cm) was significantly higher than the initial PAH (156.6±3.96 cm) (P<0.001), and it was similar to the MPH (159.9±3.52 cm). In the GnRHa plus GH group, the height SDS for BA was also increased during treatment.
AH (159.3±5.33 cm) was also higher than the initial PAH (154.6±2.55 cm) (P<0.001), which was similar to the MPH (158.1±3.31 cm). Height gain was slightly higher than that in the GnRHa alone group, however it statistically showed no significant correlation with GH treatment.
Conclusion: In CPP girls treated with GnRHa, the height SDS for BA was increased, and the AH was higher than the initial PAH. Combined GH treatment showed a limited increase in height gain.

참고문헌 (Reference)

1 Marshall WA, "Variations in pattern of pubertal changes in girls" 44 : 291-303, 1969

2 Mul D, "The use of GnRH agonists in precocious puberty" 159 (159): S3-S8, 2008

3 Bayley N, "Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards" 40 : 423-441, 1952

4 Greulich WW, "Radiographic atlas of skeletal development of the hand and wrist" Stanford University Press 1959

5 김은영, "Psychosocial Aspects in Girls with Idiopathic Precocious Puberty" 대한신경정신의학회 9 (9): 25-28, 2012

6 Lahlou N, "Pharmacokinetics and pharmacodynamics of GnRH agonists : clinical implications in pediatrics" 13 (13): 723-737, 2000

7 Traggiai C, "Outcome after depot gonadotrophinreleasing hormone agonist treatment for central precocious puberty: effects on body mass index and final height" 153 : 463-464, 2005

8 Partsch CJ, "Management and outcome of central precocious puberty" 56 : 129-148, 2002

9 Heger S, "Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function" 84 : 4583-4590, 1999

10 Pasquino AM, "Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropinreleasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function" 93 : 190-195, 2008

11 Ehrhardt AA, "Idiopathic precocious puberty in girls: long-term effects on adolescent behavior" 279 : 247-253, 1986

12 Lazar L, "Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity" 92 : 3483-3489, 2007

13 Conn PM, "Gonadotropin-releasing hormone and its analogues" 324 : 93-103, 1991

14 김한결, "Gonadotropin-releasing Hormone Stimulation Test for Precocious Puberty" 대한진단검사의학회 31 (31): 244-249, 2011

15 Pucarelli I, "Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution" 16 : 1005-1010, 2003

16 Pasquino AM, "Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone" 84 : 449-452, 1999

17 Korea Centers for Disease Control and Prevention, "2007 Korean children and adolescents growth standard: commentary for the development of 2007 growth chart" KCDC, Division of Chronic Disease Surveillance